Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.34 |
| ▸ | PARG | Q86W56 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24147138 | 0.89 | TDP1 (0.42) | TDP1LMNACYP3A4MAPTAPEX1 | |
| SCHEMBL9880933 | 0.83 | LMNA (0.40) | TDP1LMNACYP3A4MAPTAPEX1 | |
| SCHEMBL19256875 | 0.82 | TDP1 (0.34) | TDP1LMNACYP3A4MAPTAPEX1 | |
| SCHEMBL30450234 | 0.77 | NOS3 (0.43) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL20595229 | 0.77 | NOS3 (0.43) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL9883261 | 0.73 | ROCK1 (0.45) | TDP1LMNACYP3A4MAPTAPEX1 | |
| SCHEMBL24791368 | 0.73 | ROCK1 (0.41) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL15847272 | 0.73 | LMNA (0.56) | TDP1LMNACYP3A4MAPTAPEX1 | |
| SCHEMBL15911757 | 0.73 | LMNA (0.56) | TDP1LMNACYP3A4MAPTAPEX1 | |
| SCHEMBL20094072 | 0.73 | RECQL (0.41) | TDP1PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227485-A1 | METAL IRIDIUM COMPLEX AND USE THEREOF | GUANGDONG AGLAIA OPTOELECTRONIC MATERIALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227485-A1 | METAL IRIDIUM COMPLEX AND USE THEREOF | GUANGDONG AGLAIA OPTOELECTRONIC MATERIALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227485-A1 | METAL IRIDIUM COMPLEX AND USE THEREOF | IK, INTS9, CYBA | TDP1 3613/4885LMNA 3025/4885CYP3A4 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.